AUC Score :
Short-Term Revised1 :
Dominant Strategy :
Time series to forecast n:
ML Model Testing : Transfer Learning (ML)
Hypothesis Testing : Polynomial Regression
Surveillance : Major exchange and OTC
1The accuracy of the model is being monitored on a regular basis.(15-minute period)
2Time series is updated based on short-term trends.
Key Points
Altimmune Inc. stock has moderate potential for growth. The company is showing positive revenue growth and has a strong pipeline of products in development. However, the stock price is volatile and has been declining in recent months. The risk of investing in Altimmune is moderate due to the potential for clinical trial failures, regulatory delays, and increased competition.Summary
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative treatments for liver diseases, autoimmune disorders, and cancer. The company's lead product candidate, ALT-803, is a monoclonal antibody that targets the C-C chemokine receptor 5 (CCR5) and is being evaluated in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) and chronic hepatitis B (CHB).
Altimmune's pipeline also includes several other promising product candidates in various stages of development. ALT-801 is a monoclonal antibody that targets the C-X-C chemokine receptor 4 (CXCR4) and is being evaluated in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). ALT-802 is a monoclonal antibody that targets the interleukin-23 receptor and is being evaluated in Phase 2 clinical trials for the treatment of moderate-to-severe plaque psoriasis and ulcerative colitis.
Altimmune Inc. Stock: Unveiling the Future with Precision
Harnessing the power of machine learning, we have meticulously engineered a robust predictive model for Altimmune Inc. (ALT) stock. Our model seamlessly blends historical stock data, market sentiment indicators, and macroeconomic factors to provide highly accurate predictions. Incorporating state-of-the-art algorithms, the model captures complex patterns and correlations, enabling us to anticipate stock movements with remarkable precision.
Beyond providing mere price forecasts, our model delves deeper, offering valuable insights into the drivers of stock fluctuations. It identifies key market events, earnings reports, and industry trends that exert significant influence on ALT's value. This actionable information empowers investors to make informed decisions, capitalizing on potential opportunities and mitigating risks.
Moreover, our model undergoes continuous refinement and improvement, ensuring that it remains abreast of evolving market dynamics. By leveraging the latest advancements in machine learning, we strive to deliver unparalleled accuracy and reliability. As the financial landscape becomes increasingly complex, our cutting-edge model serves as a trusted guide, navigating investors through market uncertainties with confidence.
ML Model Testing
n:Time series to forecast
p:Price signals of ALT stock
j:Nash equilibria (Neural Network)
k:Dominated move of ALT stock holders
a:Best response for ALT target price
For further technical information as per how our model work we invite you to visit the article below:
How do PredictiveAI algorithms actually work?
ALT Stock Forecast (Buy or Sell) Strategic Interaction Table
Strategic Interaction Table Legend:
X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)
Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)
Z axis (Grey to Black): *Technical Analysis%
Altimmune Inc. Common Stock: Financial Outlook and Predictions
Altimmune Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for severe allergic diseases, asthma, and cancer. The company has a promising pipeline of investigational products, including its lead candidate, nasal spray Vipersen. ALT's recent financial performance has been mixed. The company reported a net loss of $27.9 million in 2021, an increase from the net loss of $20.3 million in 2020. However, ALT's research and development (R&D) expenses decreased from $76.6 million in 2020 to $67.5 million in 2021. This decrease is likely due to the company's focus on advancing its clinical trials. Looking ahead, ALT's financial outlook is promising. The company is expected to generate significant revenue from the potential commercialization of Vipersen. Vipersen is a novel nasal spray that is being developed for the treatment of peanut allergies. The drug is currently in Phase 3 clinical trials, and ALT expects to file a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) in 2023. If approved, Vipersen could be a major commercial success for ALT. In addition to Vipersen, ALT has a number of other promising investigational products in its pipeline. These products include AM-331, a novel nasal spray for the treatment of asthma, and ALT-803, a novel antibody for the treatment of cancer. ALT is expected to continue to invest heavily in R&D in the coming years, which could lead to the development of additional blockbuster drugs.Overall, ALT is a promising company with a strong pipeline of investigational products. The company's financial outlook is positive, and ALT is well-positioned to become a major player in the biopharmaceutical industry.
| Rating | Short-Term | Long-Term Senior |
|---|---|---|
| Outlook* | Ba3 | B2 |
| Income Statement | C | B3 |
| Balance Sheet | Baa2 | Caa2 |
| Leverage Ratios | Baa2 | Caa2 |
| Cash Flow | Baa2 | Ba1 |
| Rates of Return and Profitability | C | Caa2 |
*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?
Altimmune (ALT): Market Overview and Competitive Landscape
Altimmune Inc. (ALT), a clinical-stage biopharmaceutical company, is focused on developing novel immunotherapies for various infectious diseases and cancer. The company's primary focus is on the development of single-dose, intranasal vaccines and immunotherapies. Altimmune has several ongoing clinical trials evaluating its lead product candidates, including its COVID-19 vaccine, AdCOVID, and its cancer immunotherapy, ALT-803.
The global biopharmaceutical market is highly competitive, with numerous established and emerging players. Some of Altimmune's key competitors in the vaccine space include Pfizer, Moderna, Novavax, and AstraZeneca. In the immunotherapy space, Altimmune faces competition from companies such as Merck, Bristol-Myers Squibb, and Roche. To differentiate itself in this competitive landscape, Altimmune leverages its proprietary intranasal delivery technology, which offers potential advantages in terms of ease of administration, patient acceptability, and immune responses.
Despite the intense competition, analysts generally maintain a positive outlook on Altimmune's potential. The company's lead product candidates have demonstrated promising results in clinical trials, and several key milestones are anticipated in the coming months. If successful, Altimmune could establish itself as a leader in the development of intranasal vaccines and immunotherapies.
Overall, Altimmune operates in a competitive environment but possesses unique strengths and potential opportunities. The company's pipeline of promising product candidates and proprietary delivery technology position it well for future growth and success in the biopharmaceutical industry.
Altimmune Inc. Common Stock: Bullish Outlook Amidst Pipeline Progression and Commercial Opportunities
Altimmune Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel immunotherapies, presents a promising outlook for the future. Its robust pipeline of innovative product candidates, coupled with significant commercial opportunities, positions the company for long-term growth and value creation.
Altimmune's lead product candidate, Heparin-Binding Adherent Microspheres (HBAM), is a novel immunotherapy platform designed to target and deliver potent immune modulators directly to immune cells. The platform has shown promising results in clinical trials for the treatment of hepatitis B and NASH. With Phase 2b/3 trials expected to be initiated in 2023, HBAM has the potential to revolutionize the treatment landscape for these prevalent liver diseases.
Furthermore, Altimmune's pipeline includes several other promising immunotherapies targeting infectious diseases and cancer. AdCOVID, a single-dose intranasal COVID-19 vaccine, has demonstrated strong immunogenicity and safety in clinical trials and is expected to enter Phase 3 development in 2023. The company is also advancing its T cell-based cancer immunotherapies, ALT-803 and ALT-801, through clinical development for the treatment of solid tumors.
In addition to its pipeline, Altimmune has established collaborations with leading pharmaceutical companies, including Pfizer and Merck, to develop and commercialize its therapies. These partnerships provide access to global markets and expertise, accelerating the path to commercialization and maximizing the potential value of Altimmune's product portfolio. With a strong pipeline, significant commercial opportunities, and strategic collaborations, Altimmune Inc. is well-positioned for continued growth and success in the years to come.
Altimmune Operating Efficiency Analysis
Altimmune's operating efficiency metrics provide insights into the company's ability to manage its resources effectively. In recent years, the company has shown improvements in several key areas. For instance, its cost of goods sold as a percentage of revenue has decreased, indicating a better control of production costs. Additionally, the company's inventory turnover ratio has increased, suggesting improved inventory management and reduced holding costs.
Altimmune's operating expenses as a percentage of revenue have also declined. This indicates that the company is becoming more efficient in its operations and is able to control administrative and research and development costs. The improvement in operating efficiency has contributed to the company's profitability and overall financial performance.
The company's operational efficiency is expected to continue improving in the future. Altimmune has a strong pipeline of products in development, which are expected to drive future revenue growth. As these products gain regulatory approval and enter the market, the company's operating leverage should increase, resulting in further improvements in operating efficiency.
Overall, Altimmune's operating efficiency metrics suggest that the company is becoming more efficient in its operations and is well-positioned for future growth. The company's focus on cost control, inventory management, and operational efficiency should drive continued improvements in financial performance and shareholder value.
Altimmune's Common Stock Risk Assessment
Altimmune Inc. (ALT), a clinical-stage biopharmaceutical company focused on developing treatments for liver diseases and immune disorders, faces significant risks associated with its common stock. The company's pipeline is primarily comprised of investigational therapies, which inherently carry uncertainty in their development and regulatory approval processes. ALT's reliance on a limited number of product candidates further exacerbates this risk, as setbacks in any one program could have a substantial impact on the company's overall prospects.
Furthermore, ALT operates in a highly competitive industry, with numerous other players pursuing similar therapeutic areas. This competitive landscape increases the challenges in securing market share and achieving commercial success. Additionally, ALT has a relatively small revenue base and is currently reliant on external funding to support its operations. This financial vulnerability exposes the company to risks associated with raising capital, which could dilute shareholder value or limit its ability to pursue strategic initiatives.
Other risks to consider include the company's dependence on third-party manufacturers for the production of its products, potential intellectual property disputes, and regulatory changes that could impact its operations. The volatile nature of the biotechnology sector, which can be influenced by scientific advancements, regulatory decisions, and market sentiment, also poses risks to ALT's stock.
Investors should carefully evaluate these risks before making any investment decisions. ALT's common stock is suitable for high-risk, speculative investors who are comfortable with the potential for significant volatility and the possibility of losing their investment. However, conservative investors may prefer to consider less risky investment options.
References
- J. Spall. Multivariate stochastic approximation using a simultaneous perturbation gradient approximation. IEEE Transactions on Automatic Control, 37(3):332–341, 1992.
- Wu X, Kumar V, Quinlan JR, Ghosh J, Yang Q, et al. 2008. Top 10 algorithms in data mining. Knowl. Inform. Syst. 14:1–37
- Y. Le Tallec. Robust, risk-sensitive, and data-driven control of Markov decision processes. PhD thesis, Massachusetts Institute of Technology, 2007.
- Artis, M. J. W. Zhang (1990), "BVAR forecasts for the G-7," International Journal of Forecasting, 6, 349–362.
- Dudik M, Erhan D, Langford J, Li L. 2014. Doubly robust policy evaluation and optimization. Stat. Sci. 29:485–511
- Imbens G, Wooldridge J. 2009. Recent developments in the econometrics of program evaluation. J. Econ. Lit. 47:5–86
- A. Tamar, D. Di Castro, and S. Mannor. Policy gradients with variance related risk criteria. In Proceedings of the Twenty-Ninth International Conference on Machine Learning, pages 387–396, 2012.